Overview

Induced Sputum Study (0000-065)

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. The results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Fluticasone
Xhance